1 – 15 of 19
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study : high white blood cell count at diagnosis is the strongest prognostic factor
(
- Contribution to journal › Article
-
Mark
Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia : A Retrospective Multinational Study
(
- Contribution to journal › Article
- 2018
-
Mark
Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010) : a prospective, intergroup, open-label, single-arm clinical trial
(
- Contribution to journal › Article
-
Mark
Predictive value of minimal residual disease in philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
(
- Contribution to journal › Article
-
Mark
Long-term survivors of childhood cancer : cure and care—the Erice Statement (2006) revised after 10 years (2016)
(
- Contribution to journal › Article
-
Mark
Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia
(
- Contribution to journal › Article
-
Mark
The ‘Survivorship Passport’ for childhood cancer survivors
(
- Contribution to journal › Article
- 2017
-
Mark
A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1
(
- Contribution to journal › Article
- 2016
-
Mark
Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia
(
- Contribution to journal › Article
-
Mark
The SIOPE strategic plan : A European cancer plan for children and adolescents
(
- Contribution to journal › Article
- 2015
-
Mark
The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A.
(
- Contribution to journal › Article
- 2014
-
Mark
Challenges for Children and Adolescents With Cancer in Europe: The SIOP-Europe Agenda
(
- Contribution to journal › Article
-
Mark
Comparison of MRD monitoring by IG/TR rearrangement and BCR/ABL1 transcript in PH+ pediatric acute lymphoblastic leukemia patients treated with imatinib in the EsPhALL study
(
- Contribution to journal › Published meeting abstract
- 2013
-
Mark
Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype
(
- Contribution to journal › Article
- 2012
-
Mark
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study
(
- Contribution to journal › Article